Table 1 Baseline patient demographics and disease characteristics (treated set)
Study 1222.24 | Study 1222.25 | |
|---|---|---|
(n = 99) | (n = 100) | |
Sex, n (%) | ||
Male | 52 (52.5) | 54 (54.0) |
Female | 47 (47.5) | 46 (46.0) |
Age, mean (SD), years | 61.8 (8.9) | 63.5 (8.2) |
COPD diagnosis, mean (SD), years | 7.4 (5.2) | 9.4 (7.9) |
Pre-bronchodilator | ||
Mean (SD) FEV1, L | 1.241 (0.451) | 1.242 (0.504) |
Mean (SD) FEV1/FVC, % | 49.571 (11.562) | 48.673 (12.144) |
Mean (SD) % of predicted normal FEV1 | 44.904 (13.908) | 46.010 (14.678) |
Post-bronchodilator | ||
Mean (SD) FEV1, L | 1.417 (0.494) | 1.439 (0.530) |
Mean (SD) FEV1 change from | ||
pre-bronchodilator, L | 0.177 (0.158) | 0.197 (0.158) |
Mean (SD) FEV1/FVC, % | 50.224 (11.133) | 49.354 (11.460) |
Mean (SD) % of predicted normal FEV1 | 51.368 (15.009) | 53.242 (14.706) |
GOLD stage, n (%) | ||
2 | 51 (51.5) | 56 (56.0) |
3 | 39 (39.4) | 39 (39.0) |
4 | 9 (9.1) | 5 (5.0) |
BMI, mean (SD), kg/m2 | 28.7 (7.7) | 27.8 (7.2) |
Current smoker, n (%) | 60 (60.6) | 43 (43.0) |
Smoking history, mean (SD), pack-years | 54.9 (24.8) | 51.2 (26.7) |